Price
No data yet.
Social Signal Score
Analyst Ratings
7 analystsRevenue
$0.00Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Christopher A. Kroeger
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 133
- Beta
- 3.01
- Country
- US
- Piotroski score
- 2 / 9 (Weak)
- Altman Z-score
- 4.71
Financials
Net Income
$-51.62MEBITDA
$-55.34MFree Cash Flow
$-35.69MEPS (diluted)
$-0.97Shares Outstanding (diluted)
53.10M+28.2%Operating Expenses
$55.34MCash & Debt
$463.41MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $0.00 | $-161.15M | $-3.66 |
| 2024 | $0.00 | $-77.58M | $-1.87 |
| 2023 | $0.00 | $-55.71M | $-1.34 |
| 2022 | $0.00 | $-30.02M | $-0.72 |
Valuation
MPLThas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
110+10.00%Social Signal Score
Mentions (5)
- Newszacks.com·37d ago·Positive
Down 29.2% in 4 Weeks, Here's Why You Should You Buy the Dip in MapLight Therapeutics, Inc. (MPLT) The heavy selling pressure might have exhausted for MapLight Therapeutics, Inc. (MPLT) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
View source ↗ - Newszacks.com·39d ago·Neutral
Down 34.8% in 4 Weeks, Here's Why MapLight Therapeutics, Inc. (MPLT) Looks Ripe for a Turnaround MapLight Therapeutics, Inc. (MPLT) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
View source ↗ - Newsglobenewswire.com·47d ago·Negative
…nce and helped inspire MapLight's circuit-based approach to drug discovery SAN FRANCISCO and BOSTON, Oct. 06, 2026 (GLOBE NEWSWIRE) -- MapLight Therapeutics (Nasdaq: MPLT) celebrates Karl Deisseroth, M.D., Ph.D., co-founder and Scientific Advisory Board member of MapLight, who was awarded the 2026 Nobel Prize in Physiology or Medicine.
View source ↗ - Newsglobenewswire.com·74d ago·Neutral
MapLight Therapeutics to Participate in Upcoming Investor Conference SAN FRANCISCO and BOSTON, Sept. 09, 2026 (GLOBE NEWSWIRE) -- MapLight Therapeutics, Inc. (Nasdaq: MPLT) today announced that members of its management team will participate in the following investor conference:
View source ↗ - Newsglobenewswire.com·101d ago·Negative
…ight Therapeutics Announces $150 Million Private Placement Financing SAN FRANCISCO and BOSTON, Aug. 13, 2026 (GLOBE NEWSWIRE) -- MapLight Therapeutics, Inc. (Nasdaq: MPLT), a clinical-stage biopharmaceutical company focused on improving the lives of patients suffering from debilitating central nervous system disorders, announced today that it has entered into a securities purchase agreement with institutional and accredited investors to sell securities in a private placement financing (the “PIPE…
View source ↗
Earnings
Typical surprise -8.2% (median, so one quarter with a near-zero estimate can't distort it)
- Mon, Nov 16$-0.97 vs $-1.18beat
- Fri, Sep 18$-1.32 vs $-1.35beat
- Thu, Aug 13$-1.32 vs $-1.35beat
- Fri, May 15$-1.34 vs $-1.05miss
- Thu, Dec 4$-37.18 vs $-1.72miss
- Fri, Aug 22$-1.14 vs $-0.96miss
Estimates and results for MPLT via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by MPLT officers and directors.
- Bought
- $65.5m
- Sold
- $12.7m
7 trades
52 trades
- Kreitzer Anatolsold
- Gillis Jonathansold
- Lillie James Woodruffsold
- Hanson Kristophersold
- Foff Erin Pennocksold
- Kroeger Christopher A.sold
- Hanson Kristophersold
- Catalyst4, Inc.bought
28 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in MPLT.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.
